Normal LV function (N = 99) LV cardiomyopathy (N = 40)
P value
Age (y/o) 52.3 ± 13.5 55.3 ± 15.0 0.254
Male (n, %) 58 (58.6%) 32 (80.0%) 0.019
Hypertension (n, %) 17 (17.2%) 6 (15.0%) 1.000
Diabetes (n, %) 8 (8.1%) 3 (7.5%) 1.000
Symptom of Palpitation (n, %) 97 (98.0%) 40 (100.0%) 1.000
Symptom of Syncope (n, %) 10 (10.1%) 7 (17.5%) 0.257
Medication before ablation
Beta blocker or CCB only (n, %) 39 (39.4%) 15 (37.5%) 1.000
Class I AAD (n, %) 36 (36.4%) 13 (32.5%) 0.700
Amiodarone (n, %) 19 (19.2%) 12 (30.0%) 0.182
Clinical VA pattern
Presence of Sustained VT (n, %) 13 (13.1%) 12 (30.0%) 0.027
Presence of Non-Sustained VT (n, %) 33 (33.3%) 9 (22.5%) 0.228
PVC burden (pre-ablation) (beats/day) 22467 ± 12419 20597 ± 12307 0.510
PVC burden (pre-ablation) (%)* 20.9 ± 11.6 20.0 ± 11.6 0.631
Ejection fraction (pre-ablation) (%)* 58.4 ± 4.1 37.5 ± 9.3 <0.001
VA morphology
RBBB morphology (n,%) 27 (27.3%) 19 (47.5%) 0.029
Coupling interval 483.7 ± 58.8 510.5 ± 66.4 0.021
QRSd, ms 147.2 ± 20.4 163.7 ± 28.0 0.001
IDT, ms 58.2 ± 20.8 63.8 ± 21.9 0.155
PdW, ms 56.9 ± 20.7 59.9 ± 20.4 0.438
Q-wave aVL/aVR ratio 1.36 ± 0.48 1.49 ± 0.39 0.130
MDI 0.47 ± 0.13 0.46 ± 0.13 0.617
Successful ablation site (n, %)
ASV 38 (38.4%) 11 (27.5%) 0.246
Subvalvular 21 (21.2%) 8 (20.0%) 1.000
GCV/AIV 28 (28.3%) 15 (37.5%) 0.315
Epicardium 12 (12.1%) 6 (15.0%) 0.781
AEAD 12.0 ± 9.1 16.3 ± 8.2 0.012
Multiple site ablation requirement (n, %) 56 (56.6%) 22 (55.0%) 1.000